Zai Lab

Zai Lab Net Debt per Share

The Net Debt per Share of Zai Lab (9688.HK) as of Nov 22, 2026 is -0.57 USD. In the previous year, Net Debt per Share was -0.63 USD — a change of -9.74% (higher).

Net Debt per Share

-0.57USD

YoY

-9.74%

Last updated:

Net Debt per Share of Zai Lab is 2025 -0.57 USD. Net Debt per Share of Zai Lab was 2024 -0.63 USD. It decreases by -9.74% higher compared to the previous year.

The Zai Lab Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2018
-0.26 USD
Jan 1, 2019
-0.26 USD
Jan 1, 2020
-1.18 USD
Jan 1, 2021
-1.41 USD
Jan 1, 2022
-1.00 USD
Jan 1, 2023
-0.80 USD
Jan 1, 2024
-0.63 USD
Jan 1, 2025
-0.57 USD
The Zai Lab Net Debt per Share history
YEARNet Debt per ShareYoY
-0.57USD-9.74%
-0.63USD-20.86%
-0.80USD-19.92%
-1.00USD-29.10%
-1.41USD+19.29%
-1.18USD+359.64%
-0.26USD-2.12%
-0.26USD+13.06%
-0.23USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zai Lab Stock analysis

What does Zai Lab do? Zai Lab Ltd. focuses on discovering, developing, and commercializing proprietary therapeutics for unmet medical needs in China, particularly in oncology, autoimmune, and infectious diseases. The company's pipeline includes drug candidates such as Niraparib (ZL-2306), ZL-2103, and ZL-1101, which are in various stages from discovery to late-stage clinical programs. Its products target large patient segments requiring innovative treatments within the Chinese healthcare market. The firm's revenue comes from the commercialization of its proprietary drug candidates, which are developed through internal research and strategic partnerships. Zai Lab Ltd. serves the Chinese biopharmaceutical market, targeting healthcare providers, hospitals, and patients seeking advanced therapies for conditions like cancer and autoimmune disorders. The company leverages its pipeline to generate sales through pharmaceutical distribution channels in China. Zai Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zai Lab stock

Net Debt per Share of Zai Lab is -0.57 USD in 2025.

Net Debt per Share of Zai Lab changed from -0.63 USD to -0.57 USD, representing a -9.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share Zai Lab since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Zai Lab

All Key Metrics — Zai Lab